China Resources Double-Crane Pharmaceutical Co.,Ltd.

SHSE:600062 Stock Report

Market Cap: CN¥20.3b

China Resources Double-Crane PharmaceuticalLtd Dividends and Buybacks

Dividend criteria checks 3/6

China Resources Double-Crane PharmaceuticalLtd is a dividend paying company with a current yield of 1.01% that is well covered by earnings.

Key information

1.0%

Dividend yield

0.005%

Buyback Yield

Total Shareholder Yield1.0%
Future Dividend Yield1.8%
Dividend Growth13.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareCN¥0.200
Payout ratio27%

Recent dividend and buyback updates

Recent updates

The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 29
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

Oct 21
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement

An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

Sep 30
An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued

We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

Jul 16
We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24
China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02
Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: 600062's dividend payments have been volatile in the past 10 years.

Growing Dividend: 600062's dividend payments have fallen over the past 10 years.


Dividend Yield vs Market

China Resources Double-Crane PharmaceuticalLtd Dividend Yield vs Market
How does 600062 dividend yield compare to the market?
SegmentDividend Yield
Company (600062)1.0%
Market Bottom 25% (CN)0.5%
Market Top 25% (CN)2.1%
Industry Average (Pharmaceuticals)1.8%
Analyst forecast (600062) (up to 3 years)1.8%

Notable Dividend: 600062's dividend (1.01%) is higher than the bottom 25% of dividend payers in the CN market (0.55%).

High Dividend: 600062's dividend (1.01%) is low compared to the top 25% of dividend payers in the CN market (2.12%).


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (27.2%), 600062's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (19%), 600062's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 03:52
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Resources Double-Crane Pharmaceutical Co.,Ltd. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhi Xue DiaoAvic Securities Co., Ltd
Jessica LiBofA Global Research
Helena QiuCCB International Securities Limited